title: Prediction of antiarthritic drug efficacies by monitoring active matrix metalloproteinase-3 (MMP-3) levels in collagen-induced arthritic mice using the MMP-3 probe.
abstract: Active matrix metalloproteinase-3 (MMP-3) is a prognostic marker of rheumatoid arthritis (RA). We recently developed an MMP-3 probe that can specifically detect the active form of MMP-3. The aim of this study was to investigate whether detection and monitoring of active MMP-3 could be useful to predict therapeutic drug responses in a collagen-induced arthritis (CIA) model. During the period of treatment with drugs such as methotrexate (MTX) or infliximab (IFX), MMP-3 mRNA and protein levels were correlated with fluorescence signals in arthritic joint tissues and in the serum of CIA mice. Also, bone volume density and erosion in the knee joints and the paws of CIA mice were measured with microcomputed tomography (micro-CT), X-ray, and histology to confirm drug responses. In joint tissues and serum of CIA mice, strong fluorescence signals induced by the action of active MMP-3 were significantly decreased when drugs were applied. The decrease in RA scores in drug-treated CIA mice led to fluorescence reductions, mainly as a result of down-regulation of MMP-3 mRNA or protein. The micro-CT, X-ray, and histology results clearly showed marked decreases in bone and cartilage destruction, which were consistent with the reduction of fluorescence by down-regulation of active MMP-3 in drug-treated CIA mice. We suggest that the MMP-3 diagnostic kit could be used to detect and monitor the active form of MMP-3 in CIA mice serum during a treatment course and thereby used to predict the drug response or resistance to RA therapies at an earlier stage. We hope that monitoring of active MMP-3 levels in arthritis patients using the MMP-3 diagnostic kit will be a promising tool for drug discovery, drug development, and monitoring of drug responses in RA therapy.
authors.affiliation: Biomedical Research Center, Korea Institute of Science and Technology , 39-1 Hawolgok-Dong, Seongbuk-gu, Seoul 136-791, South Korea.
authors.forename: Aeju
authors.initials: A
authors.lastname: Lee
authors.forename: Kyeongsoon
authors.initials: K
authors.lastname: Park
authors.forename: Sung-Jae
authors.initials: SJ
authors.lastname: Choi
authors.forename: Dong-Hyun
authors.initials: DH
authors.lastname: Seo
authors.forename: Kwangmeyung
authors.initials: K
authors.lastname: Kim
authors.forename: Han Sung
authors.initials: HS
authors.lastname: Kim
authors.forename: Kuiwon
authors.initials: K
authors.lastname: Choi
authors.forename: Ick Chan
authors.initials: IC
authors.lastname: Kwon
authors.forename: Soo-Young
authors.initials: SY
authors.lastname: Yoon
authors.forename: Inchan
authors.initials: I
authors.lastname: Youn
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001169:Arthritis, Experimental / Q000188:drug therapy / Q000201:enzymology; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000201:enzymology; D003094:Collagen / Q000633:toxicity*; D004195:Disease Models, Animal; D000069285:Infliximab; D019278:Matrix Metalloproteinase 3 / Q000378:metabolism*; D008727:Methotrexate / Q000627:therapeutic use; D051379:Mice; D015335:Molecular Probes / Q000378:metabolism*
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D015335:Molecular Probes; D003094:Collagen; D000069285:Infliximab; D019278:Matrix Metalloproteinase 3; D008727:Methotrexate